Molecular Subtype
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002369Explore in graph →
Hematologic28 active trials
- NCIt
- C3175
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002369Explore in graph →
Clinical trials
122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (16)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 |
| Apr 29, 2022 |
| clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 10, 2022source: clinicaltrials